NRAS and colorectal carcinoma: Numerous studies have underscored the unfavorable prognosis of CRC patients harboring KRAS mutations [5]. For instance, a study conducted by Wang et al. on a cohort of 1655 patients found that KRAS mutant CRC is linked with an unfavorable prognosis (HR=1.30, p=0.008), necessitating the utilization of distinct prognostic markers [6]. Studies involving both KRAS mutation and BRAF mutation were carried out by Modest et al., de Cuba et al., and Wang et al. (the median OS for patients with WT, KRAS, NRAS, and BRAF was 49.2, 36.2, 30.1, and 22.5 months) [7-9].